Comparative Effectiveness of Ampicillin/Sulbactam versus Cefazolin as Targeted Therapy for Bacteremia Caused by Beta-Lactamase-Producing Methicillin-Sensitive <i>Staphylococcus aureus</i>: A Single-Center Retrospective Study

Comparative Effectiveness of Ampicillin/Sulbactam versus Cefazolin as Targeted Therapy for Bacteremia Caused by Beta-Lactamase-Producing Methicillin-Sensitive <i>Staphylococcus aureus</i>: A Single-Center Retrospective Study

Cefazolin (CFZ) is the first-line treatment for beta-lactamase-producing methicillin-sensitive <i>Staphylococcus aureus</i> (BP-MSSA) infection. In 2019, Japan experienced a CFZ shortage because of foreign object inclusion in a batch. Ampicillin/sulbactam (SAM) was preferred in many case...

Full description

Bibliographic Details
Main Authors: Jun Hirai, Nobuhiro Asai, Mao Hagihara, Takaaki Kishino, Hideo Kato, Daisuke Sakanashi, Wataru Ohashi, Hiroshige Mikamo
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Antibiotics
Subjects:
beta-lactamase-producing methicillin-sensitive <i>Staphylococcus aureus</i>
bacteremia
ampicillin/sulbactam
cefazolin
definitive therapy
Japan
Online Access:https://www.mdpi.com/2079-6382/11/11/1505

Similar Items

Similar Items